Table 1.

List of MET-targeted therapies in the treatment of MET aberrations in glioblastoma in clinical trials.

Study NCT Number	Summary	Conditions	Drug(s)	Mechanisms of Action	Phase
00704288	Evaluate XL184 (cabozantinib) for GBM	Glioblastoma multiforme	Drug: XL184	VEGFR2, MET, and RET inhibitor	II [104] completed
00960492	Determine safe dose of XL184 (cabozantinib)	Glioblastoma	Drug: XL184, temozolomide, radiation therapy	VEGFR2, MET, and RET kinase inhibitor	I [111] completed
01068782	Evaluate XL184 (cabozantinib) in astrocytic tumors	Grrade IV astrocytic tumors	Drug: XL184	VEGFR2, MET, and RET kinase inhibitor	II completed
01324479	Evaluate INC280 (capmatinib) for solid tumors	Solid tumors	Drug: INC280	MET inhibitor	I [114] completed
01870726	Evaluate INC280 (capmatinib) and buparlisib for recurrent glioblastoma	c-MET inhibitor, PI3K inhibitor, PTEN mutations, homozygous del. of PTEN or PTEN neg. by IHC, c-Met amplification by FISH, INC280, BKM120, buparlisib, recurrent GBM	DrugRUG: INC280, buparlisib	MET and PI3K inhibitor	I/II [115] active
02386826	Evaluate INC280 (capmatinib) and bevacizumab for recurrent glioblastoma	Glioblastoma gliosarcoma	Drug: INC280, bevacizumab	MET and VEGFR inhibitor	I completed
01441388	A study of crizotinib plus VEGF inhibitor combinations	Advanced solid tumors	Drug: crizotinib plus VEGF inhibitor combinations	MET and VEGFR inhibitor	I completed
02270034	Assess crizotinib for newly diagnosed glioblastoma	Glioblastoma multiforme (grade IV) of cerebellum	Drug: crizotinib	MET inhibitor	I completed
01632228	Assess onartuzumab and bevacizumab for recurrent glioblastoma	Glioblastoma	Drug: bevacizumab, onartuzumab, placebo	MET and VEGFR inhibitor	I [127] completed
02885324	Study cabozantinib for CNS tumors in children	Glioblastoma multiforme, anaplastic astrocytoma, malignant brain tumor, high-grade glioma	Drug: cabozantinib	VEGFR2, MET, and RET inhibitor	II completed
03175224	Study APL-101 for advanced solid tumors	Solid tumor, advanced cancer, renal cancer, gastric cancer, gastroesophageal junction adenocarcinoma, NSCLC, lung cancer, brain tumor, glioblastoma multiforme	D: APL-101 oral capsules	MET inhibitor	I/II active
03598244	Assess volitinib (savolitinib) for recurrent primary CNS tumors	Central nervous system (CNS) tumors	Drug: volitinib (savolitinib)	MET inhibitor	I active
05039281	Study atezolizumab and cabozantinib for recurrent glioblastoma	Recurrent glioblastoma, recurrent gliosarcoma	Biological: atezolizumab, Drug: cabozantinib	Atezolizumab: targets PD-L1, cabozantinib: VEGFR2, MET, and RET kinase inhibitor	I/II active